Harvard’s Rudolph Tanzi, Ph.D., a Leader in Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board

BOSTON–(BUSINESS WIRE)–Cerevance, a drug discovery and development company focused on brain
diseases, today announced that Rudolph Tanzi, Ph.D., has joined the
company as a senior-level scientific advisor. Dr. Tanzi is the Joseph P.
and Rose F. Kennedy Professor of Neurology at Harvard University and
Director of the Genetics and Aging Research Unit at Massachusetts
General Hospital.

Dr. Tanzi has published roughly 500 scientific papers, including the top
three most cited papers in the field of Alzheimer’s disease research. He
co-discovered all three familial early-onset Alzheimer’s disease (AD)
genes and several other neurological disease genes, including the gene
responsible for Wilson’s disease. As the leader of the Cure Alzheimer’s
Fund Alzheimer’s Genome Project, Dr. Tanzi has carried out multiple
genome wide association studies of thousands of Alzheimer’s families
leading to the identification of novel AD candidate genes,
including CD33 and the first two rare mutations causing late-onset AD in
the ADAM10 gene. His research on the role of zinc and copper in AD has
led to clinical trials at Prana Biotechnology. He is also working with
Steve Wagner of UCSD on gamma secretase modulators for the prevention
and treatment of Alzheimer’s.

“We look forward to drawing on Dr. Tanzi’s insights as we apply our
novel technology to central nervous system diseases,” said Mark Carlton,
Ph.D., Chief Scientific Officer of Cerevance. “His unique expertise in
the links between human genetic variation and neurodegenerative
diseases, as well as the impacted biological pathways, will help us
immensely as we select targets and advance new therapeutics.”

“I’m excited to advise Cerevance’s leadership as they build a great
neuroscience company and harness their unique technology to molecularly
profile specific neuronal populations in human tissue,” said Dr. Tanzi.
“Brain diseases, particularly neurodegenerative diseases like
Alzheimer’s, would certainly benefit from the discovery of new targets.”

Dr. Tanzi has also co-authored several books and received numerous
awards, including the two highest awards for Alzheimer’s disease
research: The Metropolitan Life Award and The Potamkin Prize. He was
included on the list of the “Harvard 100 Most Influential Alumni,” and
was chosen by the Geoffrey Beene Foundation as a “Rock Star of Science.”
In 2015, he was named by TIME magazine to the “TIME100 Most Influential
People in the World” list. Also in 2015, he and Dr. Doo Yeon Kim
received the Smithsonian American Ingenuity Award, the nation’s highest
award for invention and innovation, for their invention of
“Alzheimer’s-in-a-Dish.” He also received the Silver Innovator Award.

About Cerevance

Cerevance is a recently formed pharmaceutical company focused on central
nervous system diseases. The company’s strengths include a powerful
technology platform, a pipeline of novel discovery-stage and
clinical-stage compounds and a proven team. Its scientists believe that
they are well positioned to deliver life-changing therapeutics for
patients who have brain-related disorders.

Contacts

Cerevance
Robert Middlebrook, +1-408-220-5722